Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lacosamide (Vimpat®) cannot be endorsed for use within NHS Wales as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. |
||
|
||
Medicine details |
||
| Medicine name | lacosamide (Vimpat®) | |
| Formulation | Multiple formulations | |
| Reference number | 1295 | |
| Indication | Monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy |
|
| Company | UCB Pharma Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 03/04/2017 | |